Literature DB >> 7692230

Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.

M Dosil1, S Wang, I R Lemischka.   

Abstract

Flk2/Flt3 is a recently identified receptor tyrosine kinase expressed in brain, placenta, testis, and primitive hematopoietic cells. The mitogenic signalling potential and biochemical properties of Flk2/Flt3 have been analyzed by using a chimeric receptor composed of the extracellular domain of the human colony-stimulating factor 1 receptor and the transmembrane and cytoplasmic domains of murine Flk2/Flt3. We demonstrate that colony-stimulating factor 1 stimulation of the Flk2/Flt3 kinase in transfected NIH 3T3 fibroblasts leads to a transformed phenotype and generates a full proliferative response in the absence of other growth factors. In transfected interleukin 3 (IL-3)-dependent Ba/F3 lymphoid cells, activation of the chimeric receptor can abrogate IL-3 requirement and sustain long-term proliferation. We show that phospholipase C-gamma 1, Ras GTPase-activating protein, the p85 subunit of phosphatidylinositol 3'-kinase, Shc, Grb2, Vav, Fyn, and Src are components of the Flk2/Flt3 signal transduction pathway. In addition, we demonstrate that phospholipase C-gamma 1, the p85 subunit of phosphatidylinositol 3'-kinase, Shc, Grb2, and Src family tyrosine kinases, but not Ras GTPase-activating protein, Vav, or Nck, physically associate with the Flk2/Flt3 cytoplasmic domain. Cell-type-specific differences in tyrosine phosphorylation of p85 and Shc are observed. A comparative analysis of the Flk2/Flt3 signal cascade with those of the endogenous platelet-derived growth factor and IL-3 receptors indicates that Flk2/Flt3 displays specific substrate preferences. Furthermore, tyrosine phosphorylation of p85 and Shc is similarly affected by totally different growth factors in the same cellular background.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692230      PMCID: PMC364716          DOI: 10.1128/mcb.13.10.6572-6585.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  67 in total

1.  Signal transduction. How receptors turn Ras on.

Authors:  F McCormick
Journal:  Nature       Date:  1993-05-06       Impact factor: 49.962

2.  Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene.

Authors:  S D Lyman; L James; J Zappone; P R Sleath; M P Beckmann; T Bird
Journal:  Oncogene       Date:  1993-04       Impact factor: 9.867

3.  Molecular cloning of the mouse grb2 gene: differential interaction of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors.

Authors:  K L Suen; X R Bustelo; T Pawson; M Barbacid
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

4.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase.

Authors:  N Maroc; R Rottapel; O Rosnet; S Marchetto; C Lavezzi; P Mannoni; D Birnbaum; P Dubreuil
Journal:  Oncogene       Date:  1993-04       Impact factor: 9.867

6.  Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor.

Authors:  S A Courtneidge; R Dhand; D Pilat; G M Twamley; M D Waterfield; M F Roussel
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

7.  c-fps/fes protein-tyrosine kinase is implicated in a signaling pathway triggered by granulocyte-macrophage colony-stimulating factor and interleukin-3.

Authors:  Y Hanazono; S Chiba; K Sasaki; H Mano; A Miyajima; K Arai; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

8.  Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases.

Authors:  S Mori; L Rönnstrand; K Yokote; A Engström; S A Courtneidge; L Claesson-Welsh; C H Heldin
Journal:  EMBO J       Date:  1993-06       Impact factor: 11.598

9.  The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.

Authors:  E Y Skolnik; C H Lee; A Batzer; L M Vicentini; M Zhou; R Daly; M J Myers; J M Backer; A Ullrich; M F White
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

10.  Tyrosine 785 is a major determinant of Trk--substrate interaction.

Authors:  A Obermeier; H Halfter; K H Wiesmüller; G Jung; J Schlessinger; A Ullrich
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  49 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 2.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

3.  A proliferation switch for genetically modified cells.

Authors:  C A Blau; K R Peterson; J G Drachman; D M Spencer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 4.  Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.

Authors:  Mark Levis
Journal:  Future Oncol       Date:  2014       Impact factor: 3.404

5.  Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras.

Authors:  Nader Omidvar; Lorna Pearn; Alan K Burnett; Richard L Darley
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

6.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 9.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

10.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.